G1 Therapeutics’ COSELA™ (trilaciclib) Included in Two Updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology

NEXT STORY
Immunocore Provides Business Update and Reports Full Year 2020 Financial Results
PREV STORY
Global Bi-Specific MAbS Market Report 2020: Market is Expected to Stabilize and Reach $6.12 Billion by 2023 – Long-term Forecast to 2025 & 2030
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Gritstone Announces Positive Preclinical Data in Non-Human Primate Challenge Study with Second-Generation COVID-19 Vaccine Against SARS-CoV-2

author_avatar
NASDAQ Market News

Predictive Oncology Inc. Announces Receipt of Cash Proceeds of $2.2 Million from Exercise of Warrants

author_avatar
NASDAQ Market News

Acute Hospital Care Market Size to Hit US$ 4.58 Trillion by 2027

author_avatar
NASDAQ Market News